8-K: Marker Therapeutics Reports Strong MT-601 Data, Extends Runway

Marker Therapeutics announced encouraging clinical data for its lead MT-601 program in lymphoma, alongside Q3 2025 financial results and an extended cash runway.

Summary

• Reported Q3 2025 financial results and corporate updates on November 14, 2025.
• Phase 1 APOLLO study of MT-601 in relapsed/refractory B-cell lymphoma showed a 66% objective response rate and 50% complete response rate in heavily pre-treated Non-Hodgkin lymphoma (NHL) patients.
• Responses were durable, with five NHL patients maintaining response for 6 months and three for 12 months (range 3-24 months).
• MT-601 demonstrated a favorable safety profile with no dose-limiting toxicities (DLTs) or immune effector cell-associated neurotoxicity (ICANS).
• The first patient was treated in the Off-the-Shelf (OTS) program (RAPID study) investigating MT-401 in Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS).
• Established a cGMP manufacturing collaboration with Cellipont Bioservices to scale up MT-601 production.
• Raised approximately $10 million through an At-The-Market (ATM) facility, extending the cash runway into Q3 2026.
• Net loss from continuing operations for Q3 2025 was $2.0 million, an improvement from $2.3 million in Q3 2024.
• Research and development expenses decreased to $2.3 million in Q3 2025 from $3.5 million in Q3 2024.
• Cash and cash equivalents stood at $17.6 million, with restricted cash of $1.4 million, as of September 30, 2025.

Sentiment

Score: 8

Explanation: The filing presents strong positive clinical data for MT-601 in a challenging patient population, coupled with an improved financial position (reduced net loss, extended cash runway) and strategic operational advancements (manufacturing partnership, OTS program initiation). While grant income decreased and G&A increased slightly, the overall tone and substance point to significant progress and positive momentum for the company's pipeline and financial stability.

Positives

• MT-601 Phase 1 APOLLO study showed a 66% objective response rate and 50% complete response rate in heavily pre-treated NHL patients, including those previously treated with CAR-T cell therapies and bispecific antibodies.
• Durable responses observed in the APOLLO study, with five NHL patients maintaining response for 6 months and three for 12 months (range 3-24 months).
• Favorable safety profile for MT-601 with no dose-limiting toxicities (DLTs) or immune effector cell-associated neurotoxicity (ICANS) observed.
• First patient treated in the Off-the-Shelf (OTS) program (RAPID study) for AML/MDS, with MT-401-OTS being well tolerated.
• Secured a cGMP manufacturing agreement with Cellipont Bioservices, supporting clinical supply and future commercial readiness for MT-601.
• Strengthened the balance sheet by raising approximately $10 million through an ATM facility.
• Extended cash runway well into Q3 2026.
• Net loss improved to $2.0 million in Q3 2025 from $2.3 million in Q3 2024.
• Research and development expenses decreased to $2.3 million in Q3 2025 from $3.5 million in Q3 2024.
• Net loss per share improved to $(0.12) in Q3 2025 from $(0.26) in Q3 2024.

Negatives

• Grant income decreased to $1,232,938 in Q3 2025 from $1,926,020 in Q3 2024.
• General and administrative expenses increased to $1.0 million in Q3 2025 from $0.9 million in Q3 2024.
• The ATM facility, while extending runway, resulted in an increase in common shares outstanding from 10.7 million at December 31, 2024, to 16.7 million at September 30, 2025, indicating dilution.

Risks

• Forward-looking statements are subject to risks, uncertainties, and other factors that could cause actual results to differ materially.
• Risks include those related to research, development, and regulatory activities of non-engineered multi-tumor antigen specific T cell therapies.
• Uncertainties regarding the effectiveness, possible range of application, potential curative effects, and safety of these programs.
• Risks associated with the timing, conduct, interim results announcements, and outcomes of clinical trials of product candidates, including MT-601 for lymphoma.
• Reliance on non-dilutive funding from grants, with the cash runway projection assuming no additional grant funds are received.
• The company's ability to successfully enroll patients in clinical trials, such as the MT-601 dose expansion cohort.
• The need for further capital beyond Q3 2026 to fund operations.

Future Outlook

The company anticipates sharing additional clinical data for MT-601 in lymphoma in the first half of 2026 and expects to launch the clinical program for MT-601 in metastatic pancreatic cancer in the first half of 2026. Management is focused on enrolling patients in the MT-601 dose expansion cohort and believes its existing cash and cash equivalents will fund operating expenses through the third quarter of 2026.

Management Comments

• "Marker entered the second half of 2025 with strong clinical momentum as we continue to advance our lead program, MT-601, in patients with relapsed or refractory B-cell lymphoma."
• "The most recent update from our Phase 1 APOLLO study showed a 66% objective response rate including 50% complete responses, in heavily pre-treated NHL patients. These data, together with a favorable safety profile, reinforce the potential of MT-601 to meet the critical needs of patients who have exhausted multiple lines of therapy, including CAR-T cell therapies and bispecific antibodies."
• "We're encouraged by the durability of responses and plan to share an additional update in the first half of 2026."
• "We also achieved a number of key milestones in this quarter, including treating the first patient in our Off-the-Shelf (OTS) program and entering a strategic manufacturing collaboration with Cellipont to scale up production of MT-601."
• "In parallel, we have strengthened our balance sheet by raising approximately $10 million through our ATM facility, extending our cash runway well into 2026."
• "Looking ahead, we are focused on enrolling patients in the MT-601 dose expansion cohort to build on our promising observations from our APOLLO study."
• "Having executed on the priorities we set at the beginning of the year we are entering the final stretch of 2025 with strong operational footing and a clear clinical focus."

Industry Context

Marker Therapeutics operates in the highly competitive and innovative immuno-oncology space, specifically focusing on T-cell based therapies. The positive clinical data for MT-601 in heavily pre-treated NHL patients, including those who failed CAR-T and bispecific antibodies, positions it as a potentially significant alternative in a challenging patient population. The development of an "Off-the-Shelf" program (MT-401) is a key trend in cell therapy, aiming to overcome the logistical and cost challenges of autologous therapies. The manufacturing partnership with Cellipont Bioservices is crucial for scaling production, a common hurdle for clinical-stage cell therapy companies. The non-dilutive funding from NIH, FDA, and CPRIT highlights the recognized potential of their MAR-T cell platform within the cancer research community.

Comparison to Industry Standards

• The 66% objective response rate and 50% complete response rate for MT-601 in heavily pre-treated relapsed/refractory NHL patients, including those who failed CAR-T and bispecific antibodies, are highly encouraging. For context, approved CAR-T therapies like Yescarta (axicabtagene ciloleucel) and Kymriah (tisagenlecleucel) show overall response rates typically ranging from 50-80% in similar patient populations, but often in earlier lines of therapy or before failure of bispecifics. The ability of MT-601 to achieve these responses after failure of such advanced therapies suggests a differentiated mechanism or efficacy profile.
• The favorable safety profile with no dose-limiting toxicities (DLTs) or immune effector cell-associated neurotoxicity (ICANS) is a significant advantage compared to genetically engineered CAR-T therapies, which frequently report Grade 3 or higher cytokine release syndrome (CRS) and ICANS. This could position MT-601 as a safer alternative, potentially allowing for broader patient applicability and outpatient administration.
• The "Off-the-Shelf" (OTS) approach with MT-401 for AML/MDS is a strategic move aligning with industry efforts to develop allogeneic cell therapies. Companies like Allogene Therapeutics and CRISPR Therapeutics are also pursuing allogeneic CAR-T platforms to address the manufacturing complexities and patient access limitations of autologous therapies. Marker's non-genetically modified MAR-T cell approach could offer a unique safety and manufacturing advantage in this competitive landscape.

Management Changes

Related Party Transactions

• Related party payable decreased from $1,710,500 at December 31, 2024, to $328,315 at September 30, 2025.

Stakeholder Impact

• Shareholders: Potential positive impact due to strong clinical data, extended cash runway, and strategic advancements, but also dilution from the ATM capital raise.
• Patients (Lymphoma): Significant positive impact due to promising efficacy and favorable safety profile of MT-601, offering a new treatment option for heavily pre-treated patients.
• Patients (AML/MDS): Potential future benefit from the Off-the-Shelf MT-401 program.
• Employees: Continued operational focus and clinical momentum suggest stability and progress.
• Creditors/Suppliers: Improved cash position and extended runway reduce short-term financial risk.

Next Steps

• Share additional clinical data for MT-601 in lymphoma in the first half of 2026.
• Launch the clinical program for MT-601 in metastatic pancreatic cancer in the first half of 2026.
• Enroll patients in the MT-601 dose expansion cohort.
• Present data from the Phase 1 APOLLO study in two posters at the 67th ASH Annual Meeting and Exposition from December 6-9, 2025.

Key Dates

Recommendation

The filing reveals highly compelling clinical data for MT-601 in a very difficult-to-treat patient population (relapsed/refractory NHL post-CAR-T/bispecifics), demonstrating both high response rates (66% ORR, 50% CR) and a superior safety profile (no DLTs/ICANS) compared to existing engineered cell therapies. This positions MT-601 as a potential breakthrough. Furthermore, the company has significantly strengthened its financial position by raising $10 million, extending its cash runway well into 2026, and reducing its net loss. Strategic advancements like the Cellipont manufacturing partnership and the initiation of the Off-the-Shelf program further de-risk the pipeline and expand future opportunities. These factors collectively indicate strong operational execution, promising clinical progress, and improved financial stability, making it a compelling investment opportunity.

Keywords

Marker Therapeutics, MRKR, Immuno-oncology, T-cell therapy, MT-601, APOLLO study, Non-Hodgkin lymphoma, NHL, B-cell lymphoma, CAR-T therapy, Bispecific antibodies, Off-the-Shelf, MT-401, Acute Myeloid Leukemia, AML, Myelodysplastic Syndrome, MDS, Cellipont Bioservices, cGMP manufacturing, Clinical trial data, Financial results, Cash runway, Biotechnology, Oncology, Cell therapy